Kalaris Therapeutics (NASDAQ:KLRS) Trading 0.9% Higher – Still a Buy?

Kalaris Therapeutics Inc. (NASDAQ:KLRS) traded up 0.9% during mid-day trading on Tuesday . The stock traded as high as $4.74 and last traded at $4.68. 84,795 shares were traded during mid-day trading, a decline of 87% from the average session volume of 673,934 shares. The stock had previously closed at $4.64.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Wall Street Zen upgraded Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 17th. Raymond James Financial assumed coverage on Kalaris Therapeutics in a research note on Tuesday, September 2nd. They set a “strong-buy” rating for the company. Finally, Piper Sandler set a $3.00 target price on Kalaris Therapeutics and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $3.00.

Kalaris Therapeutics Trading Up 0.9%

The firm has a 50-day moving average price of $2.89.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.10).

Hedge Funds Weigh In On Kalaris Therapeutics

A hedge fund recently bought a new stake in Kalaris Therapeutics stock. XTX Topco Ltd purchased a new position in shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 24,234 shares of the company’s stock, valued at approximately $65,000. XTX Topco Ltd owned about 0.13% of Kalaris Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.